Body height; Bone development; Cardiovascular system; Growth hormone; Cholesterol; Female; Turner syndrome; Thyroid gland; Human
Abstract :
[en] In 44 girls with Turner's syndrome, aged 4.0-15.3 yr, the effects of biosynthetic GH (25 U/m2.week) given as once daily or twice daily injections were compared. During 1 yr of treatment, the growth rate increased similarly by 3.5 +/- 1.3 cm/yr in the once daily group and 2.7 +/- 1.8 cm/yr in the twice daily group. Although pretreatment height velocity was negatively related to age, the increase in height velocity during therapy was not. The mean progression in bone age (TW2-RUS method), during therapy was 1.3 yr in both groups. No significant change in the median insulin secretory response to an oral glucose tolerance test was found. Serum cholesterol and triglyceride concentrations did not change significantly throughout the study in either treatment group. Thyroid hormone concentrations remained within normal limits. Normal increments in left ventricular wall thickness and left ventricular mass for age and body surface were observed after 1 yr of GH treatment. We conclude that division of the daily GH dose given to Turner's syndrome patients into two injections does not result in either a significantly different growth response or different side-effects from once daily treatment during the first year of therapy.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
De Schepper, Jean
Craen, Margaretha
Massa, Guy
Heinrichs, Claudine
Maes, Marc
Du Caju, Marc
Rausin, Leon
Bourguignon, Jean-Pierre ; Université de Liège - ULiège > Département des sciences cliniques > Pédiatrie
Language :
English
Title :
Growth hormone therapy in turner’s syndrome: one versus two daily injections
Publication date :
1994
Journal title :
Journal of Clinical Endocrinology and Metabolism
ISSN :
0021-972X
eISSN :
1945-7197
Publisher :
Oxford University Press, New York, United States - New York
Escamilla RF, Hutchings JJ, Deamer WC, Li CH. 1960 Clinical experiences with human growth hormone in pituitary infantilism and in gonadal dysgenesis [Abstract]. Acta Endocrinol (Copenh). 35(Suppl 51):253.
Stahnke N. 1984 Human growth hormone treatment in short children without growth hormone deficiency. N Engl J Med. 310: 925-926.
Rosenfeld RG, Frane J, Attie KM, et al. 1992 Six-year results of a randomized prospective trial of human growth hormone and ox-androlone in Turner syndrome. J Pediatr. 121:49-55.
Raiti S, Moore WV, Van Vliet G, Kaplan SL. 1986 Growth-stimulating effects of human growth hormone therapy in patients with Turner syndrome. J Pediatr. 109:944-949.
Rongen-Westerlaken C, Wit JM, Drop SLS, et al. 1988 Methionyl human growth hormone in Turner's syndrome. Arch Dis Child. 63:1211-1217.
Takano K, Shizume K, Hibi I. 1989 Turner's syndrome: treatment of 203 patients with recombinant human growth hormone for one year. Acta Endocrinol (Copenh). 120:559-568.
Vanderschueren-Lodeweyckx M, Massa G, Maes M, et al. 1990 Growth-promoting effect of growth hormone and low dose estradiol in girls with Turner's syndrome. J Clin Endocrinol Metab. 70: 122-126.
Kollmann F, Damm M, Reinhardt D, et al. 1992 Growth promoting effects of human recombinant growth hormone in subjects with Ullrich-Turner syndrome (UTS). In: Ranke MB, Rosenfeld RG, eds. Turner syndrome: growth promoting therapies. Amsterdam: Elsevier; 201-207.
Rongen-Westerlaken C, Van Es A, Wit JM, et al. Growth hormone therapy in Turner's syndrome. AJDC. 146:817-820.
Allen DB, Fost NC. 1990 Growth hormone therapy for short stature: panacea or pandora's box? J Pediatr. 117:16-21.
Forbes AP, Engel E. 1963 The high incidence of diabetes mellitus in 41 patients with gonadal dysgeneis and their close relatives. Metabolism. 12:428-439.
Ranke MB, Pflüger H, Rosendahl W, et al. 1983 Turner syndrome: spontaneous growth in 150 cases and review of the literature. Eur J Pediatr. 141:81-88.
Pai GS, Leach DC, Weiss L, Wilf C, Van Dyke DL. 1977 Thyroid abnormalities in 20 children with Turner's syndrome. J Pediatr. 91:267-269.
Ranke MB, Stubbe P, Majewski F, Bierich JR. 1988 Spontaneous growth in Turner's syndrome. Acta Pediatr Scand. 343:22-30.
Tanner JM, Whitehouse RH, Takaishi M. 1966 Standards from birth to maturity for height, weight, height velocity and weight velocity: British children. Arch Dis Child. 41:454-471.
Rolland-Cachera MF, Sempé M, Guilloud-Bataille M, Patois E, Péquignot-Guggenbuhl F, Fautrad V. 1982 Adiposity indices in children. Am J Clin Nutr. 36:178-184.
Marshall WA, Tanner JM. 1969 Variations in the pattern of pubertal changes in girls. Arch Dis Child. 44:291-303.
T anner JM, Whitehouse RH, Marshall W A, Healy MJR, Goldstein H 1975 Assessment of skeletal maturity and prediction of adult height. London, New York: Academic Press.
Haffner SM, Stern MP, Hazuda HP, Pugh JA, Patterson JK. 1986 Hyperinsulinemia in a population at high risk for non-insulindependent diabetes mellitus. N Engl J Med. 315:220-224.
National Diabetes Data Group. 1979 Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 28:1039-1057.
Sahn DJ, DeMaria A, Kisslo J, Weyman A. 1987 Recommendations regarding quantitation in M-mode echocardiography: results of a survey of échocardiographie measurements. Circulation. 58:1072-1085.
Henry WL, Gardin JM, Ware JH. 1980 Echocardiographie measurements in normal subjects from infancy to old age. Circulation. 62:1055-1061.
Devereux RB, Alonso DR, Lutas EM, et al. 1986 Echocardiographie assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 57:450-458.
Smith PJ, Hindmarsh PC, Brook CGD. 1988 Contribution of dose and frequency of administration to the therapeutic effect of growth hormone. Arch Dis Child. 63:491-494.
Jansson JO, Albertsson-Wikland K, Eden S, Thorngren KG, Is-aksson O. 1982 Circumstantial evidence for a role of the secretory pattern of growth hormone in control of body growth. Acta Endocrinol (Copenh). 99:24-30.
Reiter JC, Craen M, Van Vliet G. 1991 Decreased growth hormone response to growth-releasing hormone in Turner's syndrome: relation to body weight and adiposity. Acta Endocrinol (Copenh). 125:38-42.
Wilson DM, Frane JW, Sherman B, et al. 1988 Carbohydrate and lipid metabolism in Turner syndrome: effect of therapy with growth hormone, oxandrolone and a combination of both. J Pediatr. 112:210-217.
Takano K, Shizume K, Hibi I, members of the committee for the treatment of Turner's syndrome. 1989 Treatment of 80 patients with Turner's syndrome with recombinant human growth hormone (YM-17798) for one year: the results of a multicentric study in Japan. Endocrinol Jpn. 36:253-260.
Wilson DM, Rosenfeld RG, Genentech Turner Collaborative Group. 1991 Effect of GH and oxandrolone on carbohydrate and lipid metabolism. In: Ranke MB, Rosenfeld RG, eds. Turner syndrome: growth hormone therapies. Amsterdam: Elsevier; 269-274.
Stahnke N, Stubbe P, Keller E, Zeisel HJ, Serono Study Group Hamburg. 1975 Effects and side-effects of GH plus oxandrolone in Turner syndrome. In: Ranke MB, Rosenfeld RG, eds. Turner syndrome: growth hormone therapies. Amsterdam: Elsevier; 241-247.
Nikkila EA, Pelkonen R. 1975 Serum lipids in acromegaly. Metabolism. 24:829-836.
Grunfeld C, Sherman BM, Cavalieri RR. 1988 The acute effects of human growth hormone administration on thyroid function in normal men. J Clin Endocrinol Metab. 67:1111-1113.
Massa G, De Zegher F, Vanderschueren-Lodeweyckx M. 1991 Effect of growth hormone therapy on thyroid status of girls with Turner's syndrome. Clin Endocrinol (Oxf). 34:205-209.
Martins JB, Kerber RE, Sherman BM, Marcus ML, Ehrhardt JC. 1977 Cardiac size and function in acromegaly. Circulation. 56: 863-868.
Savage DD, Henry WL, Eastman RC, Borer JS, Gorden P, 1979 Echocardiographie assessment of cardiac anatomy and function in acromegalic patients. Am J Med. 67:823-829.
Rowland TW, Morris AH, Biggs DE, Reiter EO. 1991 Cardiac effects of growth hormone treatment for short stature in children. J Pediatr Endocrinol. 4:19-23.
